Feature

How to recognize and treat hidden inflammation


 

Glucocorticoids and immunosuppressants

Despite therapeutic intervention, the disease can have a fatal outcome, even if the patient is young, said Dr. Müller-Ladner. Glucocorticoids are the current therapy of choice. The dose is more than 0.5 mg of prednisolone equivalent per kg of body weight. “This usually leads to a rapid improvement in the inflammation. Subsequently, every organ is thoroughly diagnosed to assess the severity of the disease and to plan further treatment steps.”

In the long term, proven immunosuppressants, such as azathioprine, mycophenolate, leflunomide, and methotrexate, can be used, just as for many other chronic inflammatory diseases. Cyclophosphamide or cyclosporine is used more rarely, owing to their side effect profiles.

Because of the B-cell dominance, B-cell–depleting therapy with rituximab is currently a highly effective therapeutic option but one that must be applied for, because such use is off label. “If the body responds well to the medication, organ function often recovers,” said Dr. Müller-Ladner.

This article was translated from the Medscape German edition. A version appeared on Medscape.com.

Pages

Recommended Reading

Think of pediatric morphea as a systemic, chronic disease, expert advises
Clinician Reviews
Methotrexate’s impact on COVID-19 vaccination: New insights made
Clinician Reviews
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
Clinician Reviews
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Clinician Reviews
Breakthrough COVID studies lend support to use of new boosters in immunosuppressed patients
Clinician Reviews
Evusheld PrEP may protect immunocompromised patients from severe COVID-19
Clinician Reviews
Metabolites may distinguish severe subtypes of PAH
Clinician Reviews
Vaccination cuts long COVID risk for rheumatic disease patients
Clinician Reviews
VEXAS syndrome: More common, variable, and severe than expected
Clinician Reviews
New tool better estimates cardiovascular risk in people with lupus
Clinician Reviews